Pre ICPR Events

About

Pre ICPR Events

About

Kayla Knopp, PhD

Enamory

Speaker Bio

Kayla Knopp, Ph.D., (she/her) is a clinical psychologist and researcher specializing in couples and intimate relationships, particularly expansive and non-traditional relationships. Her work focuses on making relationship interventions more inclusive, accessible, and effective, including psychedelic-assisted couple therapy in her position as an academic research psychologist. She also co-founded Enamory with colleague Dr. Khalifian, a therapy clinic and training institute that provides relationship education and support for the public as well as clinical training for mental health professionals. Dr. Knopp and Dr. Khalifian developed the Enamory Model of Psychedelic-Assisted Relationship Therapy and are currently implementing this model with ketamine in the U.S. Dr. Knopp also regularly provides talks and trainings to national and international audiences on topics including psychedelic-assisted couple therapy, couple-based PTSD treatment, technology-supported treatments, and diversity considerations for couples work. She currently serves as Co-Leader of the Couples Research and Treatment SIG of the Association of Behavioral and Cognitive Therapies.

ICPR 2024 Abstract

Psychedelic-Assisted Therapies for Couples and Relationships: Emerging Evidence and Future Opportunities

Psychedelic-assisted psychotherapies are emerging as promising treatments for clinical mental health problems including posttraumatic stress disorder, depression, suicidality, anxiety, and more. Although psychedelic medicines have been used in indigenous traditions for millennia, scientific research has only recently begun to turn serious attention to the potential of these substances to treat mental health disorders. Early research shows encouraging results, particularly for treatment-resistant populations. Beyond treating individuals, scientists and practitioners have begun to conceptualize ways in which psychedelic therapies may be useful for treating relational dysfunction. The proposed biological and psychological mechanisms of psychedelic medicines including 3,4-Methylenedioxymethamphetamine (MDMA), ketamine, and psilocybin include pathways that impact intimate relationships, such as triggering oxytocin release and promoting empathy. Relationship dysfunction has broad impacts on mental health, mortality, and quality of life, and although effective cognitive-behavioral relationship interventions exist, many couples do not fully recover from relationship distress by psychotherapy alone. This panel discussion will focus on the potential of psychedelic medicines to enhance the impact of evidence-based treatments for relationships. Expert panelists have experience conducting MDMA-assisted Cognitive Behavioral Conjoint Therapy for PTSD and ketamine-assisted couple therapy. The panel will discuss the growing evidence base showing the promise of these treatments, along with clinical considerations, safety and ethical concerns, the role of cultural humility in navigating the intersection of Western science with traditional medicine, and larger implications for the field of cognitive and behavioral science. The discussion will also identify areas for continued development in the evidence-based practice and practice-informed research on psychedelic therapies for couples.

© 2007-2024 ICPR by OPEN Foundation, Amsterdam, the Netherlands
© 2007-2024 ICPR by OPEN Foundation, Amsterdam, the Netherlands
© 2007-2024 ICPR by OPEN Foundation, Amsterdam, the Netherlands